NIH Zero-Embargo Public Access Policy Takes Effect: Immediate Free Access to Taxpayer-Funded Research

The End of the Embargo Era

On 1 July 2025, the United States National Institutes of Health (NIH) implemented its revised Public Access Policy, eliminating the 12-month embargo period that had been in place since 2008. Under the new policy, all peer-reviewed manuscripts resulting from NIH-funded research must be made publicly available in PubMed Central (PMC) immediately upon the official date of publication — with zero embargo.

The policy applies to any Author Accepted Manuscript (AAM) accepted for publication in a journal on or after 1 July 2025. This represents a fundamental shift in the relationship between the world's largest public biomedical funder and the scholarly publishing ecosystem.

What Changed and Why

The previous NIH Public Access Policy, in effect since 2008, required that NIH-funded manuscripts be deposited in PubMed Central within 12 months of publication. This embargo window allowed journal publishers to maintain subscription revenue from the initial period of exclusive access before content was released to the public.

The revised policy eliminates this window entirely. Key changes include:

The implementation date was accelerated from a previously planned December 31, 2025 deadline, bringing forward the zero-embargo requirement by six months.

Compliance Pathways

The NIH has established two primary routes for compliance:

Route 1: Author Submission via NIHMS

Authors or their delegates must submit the electronic version of the Author Accepted Manuscript to PubMed Central via the NIH Manuscript Submission (NIHMS) system upon acceptance. Authors must ensure that "0 months" is selected for the release delay. Submission through NIHMS is free of charge to authors.

Route 2: Publisher Direct Deposit

If a journal or publisher has a formal agreement with the National Library of Medicine (NLM), the publisher may submit the Final Published Article directly to PMC on the author's behalf for immediate release. This pathway eliminates the need for author action but depends on publisher participation.

Scope and Applicability

The policy applies broadly to all research supported in whole or in part by NIH funding, including:

• Grants (R-series, U-series, and other grant mechanisms)
• Cooperative agreements, including training grants (T-series, F-series)
• Contracts
• Other transactions (OTs)
• Intramural research conducted by NIH scientists
• Official work of NIH employees

This comprehensive scope means that even partial NIH support for a study triggers the public access requirement for the entire resulting publication.

Enforcement and Consequences

The NIH has signalled a more robust enforcement posture than under the previous policy. Key enforcement mechanisms include:

• Funding impact: Non-compliance may affect current funding, including grant renewals, and future funding decisions.
• Publication decisions: Authors are encouraged to disclose their NIH funding to publishers early and to select journals that allow deposit of the Author Accepted Manuscript into PMC without embargo.
• Institutional reporting: Universities and research institutions are expected to monitor compliance among their NIH-funded faculty.

The Broader US Open Science Context

The NIH zero-embargo policy does not exist in isolation. It forms part of a broader restructuring of US federal science policy under the Trump administration's "Gold Standard Science" initiative:

• 23 May 2025: Executive Order 14303, "Restoring Gold Standard Science," signed by President Trump
• 23 June 2025: OSTP issued guidance requiring federal agencies to develop implementation plans for nine Gold Standard Science tenets within 60 days
• 1 July 2025: NIH zero-embargo public access policy takes effect
• 22 August 2025: Federal agencies required to submit Gold Standard Science implementation reports to OSTP

The Gold Standard Science framework defines nine core tenets: reproducible, transparent, communicative of error and uncertainty, collaborative and interdisciplinary, skeptical of findings and assumptions, structured for falsifiability of hypotheses, subject to unbiased peer review, accepting of negative results, and without conflicts of interest.

Implications for the Global Research Community

The NIH policy has ripple effects far beyond US borders. International researchers who collaborate on NIH-funded projects, or whose institutions receive NIH sub-awards, are subject to the same public access requirements. This creates a de facto global open access mandate for a significant portion of biomedical research.

For publishers, the elimination of embargo periods removes a key revenue protection mechanism. Journals that have relied on subscription income from the first 12 months of article availability will need to adapt their business models — whether through Read and Publish agreements, APC-based open access, or alternative models such as Subscribe to Open.

For researchers in low- and middle-income countries, the policy is unambiguously beneficial: NIH-funded research that was previously behind paywalls for up to a year will now be available immediately, supporting evidence-based practice, policy development, and further research without the delay or cost of interlibrary loans.

---

Sources:

• NIH Public Access Policy, revised 2025 (effective 1 July 2025)
• CITI Program, "NIH Public Access Policy Now Mandates Zero Embargo," 2025
• Washington University in St. Louis, Becker Library, "NIH Public Access Policy for Publications: Embargo Notes"
• Duke University Medical Center Library, "New NIH Public Access Policy Effective July 1, 2025"
• University of Pittsburgh School of Medicine, "NIH Public Access Policy Begins July 1"
• University of California Office of Scholarly Communication, NIH Public Access 2025